The role of modern emollients in prophylaxis of atopic dermatitis exacerbation during pollination season

BACKGROUND: Skin epidermal barrier impairment in atopic dermatitis (AD) patients facilitates percutaneous penetration of allergens and leads to maintenance of skin inflammation and primary sensitization to the allergens. We hypothesized that skin care products may have a positive effect on the course of the disease in patients with AD and pollen sensitization during the pollen season. AIMS: The aim of our study was to investigate the clinical efficacy and safety of La Roche Posay formulas: Lipikar Syndet and Lipikar Baume AP+M in the prevention of AD exacerbations in children and adults, sensitized to different pollen allergens during the pollination season. MATERIALS AND METHODS: Sixty patients aged 5 to 60 years with clinical history of mild to moderate AD sensitized to different pollen allergens were enrolled in a single-center, simple, open, prospective comparative study, and formed 2 groups. The main group used Lipikar Syndet and Baume AP+M daily with standard AD treatment for 28 days during the pollen season. The control group received only standard therapy. The study included 3 visits: at each visit, the severity of AD (SCORAD), quality of life (DLQI/CDLQI), pruritus intensity (NRS), and corneometry were assessed. The changes in the SCORAD were considered to be the primary endpoint of the study. RESULTS: A decrease of SCORAD in the main group was registered by day 14 of the study (p0.0001), while no changes of SCORAD in the control group. SCORAD in the main group was lower than in the control group (p= 0.005 ) by day 28 of the study. At the secondary endpoints was shown that in the main group the quality of life improved by the day 28 of the study (p=0.0005), the intensity of pruritus decreased (p0.0001) and the level of skin hydration increased (p0.0001) by the day 14 of the study compared to the control group. No adverse events were reported. CONCLUSIONS: Daily use of Lipikar Syndet and Lipikar Baume AP+M by patients with AD and pollen allergy during the pollen season significantly improved the course of AD, reducing the skin itching, improving skin hydration and patients quality of life.